GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GRAIL Inc (MEX:GRAL) » Definitions » Sloan Ratio %

GRAIL (MEX:GRAL) Sloan Ratio % : -38.09% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is GRAIL Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

GRAIL's Sloan Ratio for the quarter that ended in Sep. 2024 was -38.09%.

As of Sep. 2024, GRAIL has a Sloan Ratio of -38.09%, indicating there is a warning stage of accrual build up.


GRAIL Sloan Ratio % Historical Data

The historical data trend for GRAIL's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRAIL Sloan Ratio % Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23
Sloan Ratio %
3.92 -20.79 -97.51 -17.25

GRAIL Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -17.78 -13.62 -59.63 -38.09

Competitive Comparison of GRAIL's Sloan Ratio %

For the Diagnostics & Research subindustry, GRAIL's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRAIL's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where GRAIL's Sloan Ratio % falls into.



GRAIL Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

GRAIL's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-21789.027--10113.257
--218.747)/66434.049
=-17.25%

GRAIL's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-34372.498--10834.724
--152.913)/61393.45
=-38.09%

GRAIL's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -93.257 (Dec. 2023 ) + -2760.87 (Mar. 2024 ) + -29043.537 (Jun. 2024 ) + -2474.834 (Sep. 2024 ) = MXN-34,372 Mil.
GRAIL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -2187.947 (Dec. 2023 ) + -3440.171 (Mar. 2024 ) + -3147.375 (Jun. 2024 ) + -2059.231 (Sep. 2024 ) = MXN-10,835 Mil.
GRAIL's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -66.115 (Dec. 2023 ) + -42.287 (Mar. 2024 ) + -25.392 (Jun. 2024 ) + -19.119 (Sep. 2024 ) = MXN-153 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GRAIL  (MEX:GRAL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, GRAIL has a Sloan Ratio of -38.09%, indicating there is a warning stage of accrual build up.


GRAIL Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of GRAIL's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


GRAIL Business Description

Comparable Companies
Traded in Other Exchanges
Address
1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.